Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
13 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Minjuvi“
Suchtreffer
Begriffe & Kennungen
Minjuvi · 4.8 · Infections and infestations Viral infectionsb Very common Very common Bacterial infectionsc Very common Common
Eintrag öffnenMinjuvi · 4.8 · Infusion-related reactions In the L-MIND study, infusion-related reactions occurred in 6% of patients. All inf
Eintrag öffnenMinjuvi · 4.8 · Myelosuppression Treatment with tafasitamab can cause serious or severe myelosuppression including neutropenia
Eintrag öffnenMinjuvi · 4.8 · Neutropenia/febrile neutropenia In the L-MIND study, incidence of neutropenia was 51%. Incidence of Grade 3 or
Eintrag öffnenMinjuvi · 4.8 · Patients with relapsed or refractory FL after at least one line of systemic therapy The safety of tafasitamab
Eintrag öffnenMinjuvi · 4.8 · Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medi
Eintrag öffnenMinjuvi · 4.8 · Summary of the safety profile Patients with relapsed or refractory DLBCL The safety of tafasitamab in patients
Eintrag öffnenMinjuvi · 4.8 · System organ class / Adverse All grades Grade 3-4a reaction frequency frequency
Eintrag öffnenMinjuvi · 4.8 · Table 2: Adverse reactions in patients with relapsed or refractory DLBCL who received tafasitamab in combinati
Eintrag öffnenMinjuvi · 4.8 · Tabulated list of adverse reactions Adverse reactions reported for tafasitamab in clinical trials are listed b
Eintrag öffnenMinjuvi · 4.8 · The adverse reaction frequencies from clinical trials are based on all-cause adverse event frequencies, where
Eintrag öffnenMinjuvi · 4.8 · The most common serious adverse reactions were infections (26%), including viral infections (13%), and bacteri
Eintrag öffnenMinjuvi · 4.8 · Thrombocytopenia In the L-MIND study, incidence of thrombocytopenia was 31%. Incidence of Grade 3 or 4 thrombo
Eintrag öffnen